Vaxcyte
PCVX
294 hedge funds and large institutions have $4.8B invested in Vaxcyte in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 132 increasing their positions, 76 reducing their positions, and 75 closing their positions.
124% more call options, than puts
Call options by funds: $12M | Put options by funds: $5.37M
74% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 76
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
1.04% more ownership
Funds ownership: 113.3% → 114.35% (+1%)
7% less funds holding
Funds holding: 315 → 294 (-21)
18% less capital invested
Capital invested by funds: $5.88B → $4.8B (-$1.09B)
24% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 75
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$108M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$95.9M |
| 3 |
D.E. Shaw & Co
New York
|
+$72.8M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$55M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$45.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$70.5M |
| 2 |
CC
Commodore Capital
New York
|
-$62.3M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$51.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.9M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
-$43.9M |
PCVX Hedge Fund Activity: Q2 2025 in Review
294 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2025, worth a combined $4.8B — down 18% from $5.88B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of PCVX and 57 opened new positions — a net loss of 18 holders — while 76 trimmed existing stakes and 132 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $108M. The largest seller was Franklin Resources, cutting an estimated $70.5M.
- 294 institutional investors held Vaxcyte (PCVX) as of Q2 2025, down from 315 in Q1 2025.
- Funds reported $4.8B of Vaxcyte stock for Q2 2025, down 18% quarter-over-quarter.
- 57 funds opened new Vaxcyte positions in Q2 2025 and 75 closed out, a net change of -18 holders.
- The largest Vaxcyte buyer in Q2 2025 was T. Rowe Price Investment Management, an estimated $108M added.
- The largest Vaxcyte seller in Q2 2025 was Franklin Resources, an estimated $70.5M sold.
Based on aggregated 13F filings for Q2 2025.